rs730881619
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_000059.4(BRCA2):c.9891_9894dup(p.Gln3299IlefsTer29) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000657 in 152,206 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★★). Synonymous variant affecting the same amino acid position (i.e. A3297A) has been classified as Likely benign.
Frequency
Consequence
NM_000059.4 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
BRCA2 | NM_000059.4 | c.9891_9894dup | p.Gln3299IlefsTer29 | frameshift_variant | 27/27 | ENST00000380152.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
BRCA2 | ENST00000380152.8 | c.9891_9894dup | p.Gln3299IlefsTer29 | frameshift_variant | 27/27 | 5 | NM_000059.4 | A2 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152206Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251220Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135768
GnomAD4 exome Cov.: 31
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152206Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74360
ClinVar
Submissions by phenotype
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 27, 2022 | Frameshift variant predicted to result in protein truncation in a gene for which loss of function is a known mechanism of disease; Observed in individuals with prostate cancer (Matejcic 2020); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Not observed at significant frequency in large population cohorts (gnomAD); Also known as 10119_10122dup; This variant is associated with the following publications: (PMID: 9126738, 30787465, 32832836, 29922827) - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Dec 04, 2018 | DNA sequence analysis of the BRCA2 gene demonstrated a 4 base pair deletion in exon 27, c.9891_9894dup. This sequence change results in an amino acid frameshift and creates a premature stop codon 28 amino acids downstream of the mutation, p.Gln3299Ilefs*29. This pathogenic sequence change is predicted to result in the production of a truncated BRCA2 protein with potentially abnormal function. While this particular variant has not been previously reported in the literature, loss-of-function variants in BRCA2 have been described in patients with breast and/or ovarian cancer. - |
Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | May 25, 2018 | - - |
Familial cancer of breast Pathogenic:2
Pathogenic, flagged submission | clinical testing | GeneDx | Dec 13, 2013 | This variant is denoted BRCA2 c.9894_9895insATTT (aka c.9891_9894dupATTT) at the cDNA level and p.Gln3299IlefsX29 (Q3299IfsX29) at the protein level. The normal sequence with the bases that are duplicated in brackets is AGGC{ATTT}CAGC. The duplication causes a frameshift, changing a Glutamine to an Isoleucine at codon 3299, and creating a premature stop codon at position 29 of the new reading frame. This mutation is predicted to cause loss of normal protein function through protein truncation. Although this mutation has not been previously reported to our knowledge, it is considered pathogenic and is indicative of Hereditary Breast and Ovarian Cancer (HBOC) syndrome, an autosomal dominant condition that predisposes to breast and ovarian cancer as well as other cancers. The predominant BRCA2-related cancer risks for women who have not been diagnosed with cancer have been estimated as 41% - 84% lifetime risk for breast cancer and 11% - 27% lifetime risk for ovarian cancer (Ford 1998, Risch 2006). BRCA2 mutations have also been reported in women with fallopian tube carcinoma, primary peritoneal carcinoma, and uterine serous carcinoma (Levine 2003, Biron-Shental 2006). Women with BRCA1/2 mutations also have an increased risk for contralateral breast cancer. Women with BRCA mutations whose first cancer was diagnosed under age 40 have a 21-31% risk to develop a second breast cancer within 10 years and a 63% risk to develop a second breast cancer within 25 years. Women with BRCA mutations whose first cancer was diagnosed between ages 40 and 50 have an 11-13% risk to develop a second breast cancer within 10 years and a 44-49% risk within 25 years. Women with BRCA mutations whose first cancer was diagnosed after age 50 have an 8% risk to develop a second breast cancer within 10 years and a 20% risk within 25 years (Graeser 2009). Other cancer risks associated with a BRCA2 mutation include up to a 7% risk for pancreatic cancer (Ozcelik 1997, The Breast Cancer Linkage Consortium 1999), up to a 34% risk for prostate cancer in male carriers (Thompson 2001), and up to a 7% risk for male breast cancer (Liede 2004). The variant is found in BRCA1-BRCA2 panel(s). - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Oct 02, 2022 | - - |
Breast-ovarian cancer, familial, susceptibility to, 2 Pathogenic:1
Pathogenic, reviewed by expert panel | curation | Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) | Sep 08, 2016 | Variant allele predicted to encode a truncated non-functional protein. - |
Fanconi anemia complementation group D1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center | Jul 13, 2023 | PVS1, PM2, PS4_supporting - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 15, 2024 | The c.9891_9894dupATTT pathogenic mutation, located in coding exon 26 of the BRCA2 gene, results from a duplication of ATTT at nucleotide positions 9891 to 9894, causing a translational frameshift with a predicted alternate stop codon (p.Q3299Ifs*29). This alteration occurs at the 3' terminus of theBRCA2 gene, is not expected to trigger nonsense-mediated mRNA decay, and only impacts the last 3.5% of the protein. However, premature stop codons are typically deleterious in nature, and the impacted region is critical for protein function (Ambry internal data). This mutation alters the last 29 amino acids of the RAD51 binding region of the native BRCA2 protein. One study previously reported the importance of this region in the interaction between BRCA2 and RAD51 proteins during recombination-mediated DNA repair function (Davies et al. Nat. Struct. Mol. Biol. 2007 Jun 14(6):475–483). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Hereditary breast ovarian cancer syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Mar 01, 2023 | This sequence change creates a premature translational stop signal (p.Gln3299Ilefs*29) in the BRCA2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 120 amino acid(s) of the BRCA2 protein. This variant is present in population databases (rs756361508, gnomAD 0.01%). This premature translational stop signal has been observed in individual(s) with BRCA2-related conditions (PMID: 21520333). ClinVar contains an entry for this variant (Variation ID: 182326). This variant disrupts a region of the BRCA2 protein in which other variant(s) (p.Tyr3308*) have been determined to be pathogenic (PMID: 17026620, 18593900, 18607349, 22711857). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at